CoChat

CD4+ T cell activation and inflammation in NASH-related fibrosis

Open access
Zhou, Yunfeng, Zhang, Haibo, Yao, Yao, Zhang, Xiaoyan, Guan, Youfei, Zheng, Feng · 2022 · Frontiers in Immunology
Cited by 106

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

Liver fibrosis is a common pathological feature of end stage liver failure, a severe life-threatening disease worldwide. Nonalcoholic fatty liver disease (NAFLD), especially its more severe form with steatohepatitis (NASH), results from obesity, type 2 diabetes and metabolic syndrome and becomes a leading cause of liver fibrosis. Genetic factor, lipid overload/toxicity, oxidative stress and inflammation have all been implicated in the development and progression of NASH. Both innate immune response and adaptive immunity contribute to NASH-associated inflammation. Innate immunity may cause inflammation and subsequently fibrosis via danger-associated molecular patterns. Increasing evidence indicates that T cell-mediated adaptive immunity also provokes inflammation and fibrosis in NASH via cytotoxicity, cytokines and other proinflammatory and profibrotic mediators. Recently, the single-cell transcriptome profiling has revealed that the populations of CD4+ T cells, CD8+ T cells, γδ T cells, and TEMs are expanded in the liver with NASH. The activation of T cells requires antigen presentation from professional antigen-presenting cells (APCs), including macrophages, dendritic cells, and B-cells. However, since hepatocytes express MHCII molecules and costimulators, they may also act as an atypical APC to promote T cell activation. Additionally, the phenotypic switch of hepatocytes to proinflammatory cells in NASH contributes to the development of inflammation. In this review, we focus on T cells and in particular CD4+ T cells and discuss the role of different subsets of CD4+ T cells including Th1, Th2, Th17, Th22, and Treg in NASH-related liver inflammation and fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2022.967410

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Research works printed but not linked: 66

  1. Rinella, 2015, Nonalcoholic fatty liver disease: a systematic review, JAMA, 313, 10.1001/jama.2015.5370 · DOI · Paper page
  2. Cariou, 2021, Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review, Diabetes Obes Metab, 23, 10.1111/dom.14322 · DOI · Paper page
  3. Mishra, 2012, Epidemiology and natural history of non-alcoholic fatty liver disease, J Clin Exp Hepatol, 2, 10.1016/S0973-6883(12)60102-9 · DOI
  4. Estes, 2018, Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, united kingdom, and united state or the period 2016-2030, J Hepatol, 69, 896, 10.1016/j.jhep.2018.05.036 · DOI · Paper page
  5. Zhou, 2020, Epidemiological features of NAFLD from 1999 to 2018 in China, Hepatology, 71, 10.1002/hep.31150 · DOI · Paper page
  6. Lindenmeyer, 2018, The natural history of nonalcoholic fatty liver disease-an evolving view, Clin Liver Dis, 22, 11, 10.1016/j.cld.2017.08.003 · DOI · Paper page
  7. Noureddin, 2018, NASH leading cause of liver transplant in women: Updated analysis of indications for liver transplant and ethnic and gender variances, Am J Gastroenterol, 113, 10.1038/s41395-018-0088-6 · DOI · Paper page
  8. Chen, 2020, Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, Free Radic Biol Med, 152, 10.1016/j.freeradbiomed.2020.02.025 · DOI · Paper page
  9. Arroyave-Ospina, 2021, Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: Implications for prevention and therapy, Antioxidants (Basel), 10, 10.3390/antiox10020174 · DOI · Paper page
  10. Martinon, 2008, Detection of immune danger signals by NALP3, J Leukoc Biol, 83, 10.1189/jlb.0607362 · DOI · Paper page
  11. Cai, 2017, NLRP3 deletion inhibits the non-alcoholic steatohepatitis development and inflammation in kupffer cells induced by palmitic acid, Inflammation, 40, 10.1007/s10753-017-0628-z · DOI
  12. Gaul, 2021, Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis, J Hepatol, 74, 10.1016/j.jhep.2020.07.041 · DOI · Paper page
  13. Krenkel, 2017, Liver macrophages in tissue homeostasis and disease, Nat Rev Immunol, 17, 10.1038/nri.2017.11 · DOI · Paper page
  14. Krenkel, 2018, Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis, Hepatology, 67, 10.1002/hep.29544 · DOI · Paper page
  15. Kesar, 2014, Toll-like receptors and liver disease, Liver Int, 34, 10.1111/liv.12315 · DOI
  16. Petrasek, 2013, Toll-like receptors in liver disease, Adv Clin Chem, 59, 155, 10.1016/b978-0-12-405211-6.00006-1 · DOI
  17. Bieghs, 2014, Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease, Hepatobiliary Surg Nutr, 3, 10.3978/j.issn.2304-3881.2014.12.04 · doi:10.3978/j.issn.2304-3881.2014.12.04 · Paper page
  18. Pennington, 2005, The integration of conventional and unconventional T cells that characterizes cell-mediated responses, Adv Immunol, 87, 27, 10.1016/S0065-2776(05)87002-6 · DOI
  19. Godfrey, 2015, The burgeoning family of unconventional T cells, Nat Immunol, 16, 10.1038/ni.3298 · DOI · Paper page
  20. Haas, 2019, Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution, Nat Metab, 1, 10.1038/s42255-019-0076-1 · DOI · Paper page
  21. Yuseff, 2013, How b cells capture, process and present antigens: a crucial role for cell polarity, Nat Rev Immunol, 13, 10.1038/nri3469 · DOI · Paper page
  22. Fillatreau, 2018, B cells and their cytokine activities implications in human diseases, Clin Immunol, 186, 26, 10.1016/j.clim.2017.07.020 · DOI · Paper page
  23. Freitas-Lopes, 2017, Differential location and distribution of hepatic immune cells, Cells, 6, 10.3390/cells6040048 · DOI · Paper page
  24. Kambayashi, 2014, Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell, Nat Rev Immunol, 14, 10.1038/nri3754 · DOI · Paper page
  25. Zhou, 2021, MHC class II in renal tubules plays an essential role in renal fibrosis, Cell Mol Immunol, 18, 10.1038/s41423-021-00763-z · DOI
  26. Franco, 1988, Expression of class I and class II major histocompatibility complex antigens on human hepatocytes, Hepatology, 8, 10.1002/hep.1840080302 · DOI · Paper page
  27. Koch, 2010, Hypothesis: Targeted ikkβ deletion upregulates MIF signaling responsiveness and MHC class II expression in mouse hepatocytes, Hepat Med, 2010, 39, 10.2147/HMER.S7208 · DOI
  28. Dienes, 1987, Immunoelectron microscopic observations on the inflammatory infiltrates and HLA antigens in hepatitis b and non-a, non-b, Hepatology, 7, 10.1002/hep.1840070623 · DOI
  29. Lu, 2020, Overexpression of MHCII by hepatocytes in alcoholic hepatitis (AH) compared to non-alcoholic steatohepatitis (NASH) and normal controls, Alcohol, 84, 27, 10.1016/j.alcohol.2019.08.008 · DOI
  30. Alcover, 2018, Cell biology of T cell receptor expression and regulation, Annu Rev Immunol, 36, 10.1146/annurev-immunol-042617-053429 · DOI · Paper page
  31. Shah, 2021, T Cell receptor (TCR) signaling in health and disease, Signal Transduct Target Ther, 6, 412, 10.1038/s41392-021-00823-w · DOI · Paper page
  32. Liang, 2020, The T cell receptor immune repertoire protects the liver from reconsitution, Front Immunol, 11, 10.3389/fimmu.2020.584979 · DOI · Paper page
  33. Goronzy, 2008, T-Cell co-stimulatory pathways in autoimmunity, Arthritis Res Ther, S3, 10.1186/ar2414 · DOI
  34. Boleto, 2018, Targeting costimulatory pathways in systemic sclerosis, Front Immunol, 9, 10.3389/fimmu.2018.02998 · DOI
  35. Webb, 2016, OX40, OX40L and autoimmunity: a comprehensive review, Clin Rev Allergy Immunol, 50, 10.1007/s12016-015-8498-3 · DOI · Paper page
  36. Sun, 2018, OX40 regulates both innate and adaptive immunity and promotes nonalcoholic steatohepatitis, Cell Rep, 25, 3786, 10.1016/j.celrep.2018.12.006 · DOI · Paper page
  37. Publicover, 2018, An OX40/OX40L interaction directs successful immunity to hepatitis b virus, Sci Transl Med, 10, 10.1126/scitranslmed.aah5766 · DOI
  38. Heymann, 2016, Immunology in the liver–from homeostasis to disease, Nat Rev Gastroenterol Hepatol, 13, 88, 10.1038/nrgastro.2015.200 · DOI · Paper page
  39. Her, 2020, CD4 + T cells mediate the development of liver fibrosis in high fat diet-induced NAFLD in humanized mice, Front Immunol, 11, 10.3389/fimmu.2020.580968 · DOI · Paper page
  40. Saigusa, 2020, T Cell subsets and functions in atherosclerosis, Nat Rev Cardiol, 17, 387, 10.1038/s41569-020-0352-5 · DOI · Paper page
  41. Ferreyra Solari, 2012, The role of innate cells is coupled to a Th1-polarized immune response in pediatric nonalcoholic steatohepatitis, J Clin Immunol, 32, 10.1007/s10875-011-9635-2 · DOI · Paper page
  42. Shimamura, 2008, Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model, J Immunol, 181, 10.4049/jimmunol.181.7.4656 · DOI · Paper page
  43. Gao, 2016, IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis, Oncotarget, 7, 10.18632/oncotarget.9259 · DOI · Paper page
  44. Tan, 2013, IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation, J Immunol, 191, 10.4049/jimmunol.1203013 · DOI · Paper page
  45. Wang, 2014, Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes, Nature, 514, 10.1038/nature13564 · DOI · Paper page
  46. Yang, 2010, Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22, J Hepatol, 53, 10.1016/j.jhep.2010.03.004 · DOI · Paper page
  47. Zhu, 2008, CD4 T cells: fates, functions, and faults, Blood, 112, 10.1182/blood-2008-05-078154 · DOI · Paper page
  48. Zhang, 2017, 'Repair' treg cells in tissue injury, Cell Physiol Biochem, 43, 10.1159/000484295 · DOI · Paper page
  49. O'Garra, 2004, Development and function of T helper 1 cells, Adv Immunol, 83, 10.1016/S0065-2776(04)83004-9 · DOI
  50. Kremer, 2006, Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis, Hepatology, 10.1002/hep.21221 · DOI · Paper page
  51. Nakayama, 2017, Th2 cells in health and disease, Annu Rev Immunol, 35, 53, 10.1146/annurev-immunol-051116-052350 · DOI · Paper page
  52. Molina, 2019, Type 3 cytokines in liver fibrosis and liver cancer, Cytokine, 124, 154497, 10.1016/j.cyto.2018.07.028 · DOI
  53. Vonghia, 2015, CD4+ROR γ t++ and tregs in a mouse model of diet-induced nonalcoholic steatohepatitis, Mediators Inflammation, 2015, 10.1155/2015/239623 · DOI · Paper page
  54. He, 2017, The imbalance of Th17/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice, BMC Immunol, 18, 33, 10.1186/s12865-017-0215-y · DOI
  55. Xu, 2013, Neutralization of interleukin-17 attenuates high fat diet-induced non-alcoholic fatty liver disease in mice, Acta Biochim Biophys Sin (Shanghai), 45, 10.1093/abbs/gmt065 · DOI · Paper page
  56. Harley, 2014, IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice, Hepatology, 59, 10.1002/hep.26746 · DOI · Paper page
  57. Jiang, 2021, Role of Th22 cells in the pathogenesis of autoimmune diseases, Front Immunol, 12, 10.3389/fimmu.2021.688066 · DOI
  58. Jiang, 2011, Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3, Hepatology, 54, 10.1002/hep.24486 · DOI · Paper page
  59. Mangodt, 2015, The role of Th17 and treg responses in the pathogenesis of RSV infection, Pediatr Res, 78, 10.1038/pr.2015.143 · DOI
  60. Xu, 2017, PPAR-γ agonist ameliorates liver pathology accompanied by increasing regulatory b and T cells in high-fat-diet mice, Obes (Silver Spring), 25, 10.1002/oby.21769 · DOI
  61. Ma, 2007, A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury, Hepatology, 46, 10.1002/hep.21823 · DOI · Paper page
  62. Ilan, 2010, Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice, Proc Natl Acad Sci U.S.A., 107, 10.1073/pnas.0908771107 · DOI · Paper page
  63. Söderberg, 2011, Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis, APMIS, 119, 10.1111/j.1600-0463.2011.02746.x · DOI · Paper page
  64. Katz, 2011, Obstructive jaundice expands intrahepatic regulatory T cells, which impair liver T lymphocyte function but modulate liver cholestasis and fibrosis, J Immunol, 187, 10.4049/jimmunol.1004077 · DOI · Paper page
  65. Racanelli, 2006, The liver as an immunological organ, Hepatology, 43, 10.1002/hep.21060 · DOI · Paper page
  66. Wang, 2020, γδ T cells and CD1d, novel immune players in alcoholic and nonalcoholic steatohepatitis, Hepatology, 71, 10.1002/hep.31025 · DOI

Cited by

See all 106

Metadata

Authors
Zhou, Y., Zhang, H., Yao, Y., Zhang, X., Guan, Y., & Zheng, F.
Venue
Frontiers in Immunology
Published
2022-08-10
Volume
13
Pages
967410-967410
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4293778079
Cited by
106
References
45
FWCI
13.93
Type
journal article
Language
en
Open access
gold
Funders
  • National Natural Science Foundation of China (81970606, 81970595, 81970636, 81970642)
  • Shenzhen Technical Project

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD4+ T cell activation and inflammation in NASH-related fibrosis. https://app.cochat.ai/papers/10.3389/fimmu.2022.967410
The paper
Zhou, Y., Zhang, H., Yao, Y., Zhang, X., Guan, Y., & Zheng, F. (2022). CD4+ T cell activation and inflammation in NASH-related fibrosis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2022.967410

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.